aspirin enteric coated
Selected indexed studies
- [Enteric-coated aspirin does not reduce the risk of gastrointestinal side effects]. (Ugeskr Laeger, 2014) [PMID:25096559]
- Enteric-Coated Aspirin Induces Small Intestinal Injury via the Nrf2/Gpx4 Pathway: A Promising Model for Chronic Enteropathy. (Drug Des Devel Ther, 2025) [PMID:39959119]
- Enteric-coated aspirin. (South Med J, 1983) [PMID:6823616]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. (2018) pubmed
- Low-Dose Enteric-Coated and Chewable Aspirin Are Not Equally Effective in Preventing Venous Thromboembolism in Total Knee and Hip Arthroplasty. (2024) pubmed
- [Enteric-coated aspirin does not reduce the risk of gastrointestinal side effects]. (2014) pubmed
- Enteric-Coated Aspirin Induces Small Intestinal Injury via the Nrf2/Gpx4 Pathway: A Promising Model for Chronic Enteropathy. (2025) pubmed
- Enteric-coated aspirin. (1983) pubmed
- Risk of gastric injury with enteric- versus nonenteric-coated aspirin. (2002) pubmed
- Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. (1988) pubmed
- Enteric coated aspirin. (2007) pubmed
- Poisoning with enteric-coated aspirin. (1981) pubmed
- Pharmacokinetic Study of Enteric-Coated Sustained-Release Aspirin Tablets in Healthy Chinese Participants. (2023) pubmed